Milademetan in Advanced Solid Tumors with <i>MDM2</i> Amplification and Wild-type <i>TP53</i>: Preclinical and Phase II Clinical Trial Results
Milademetan had a manageable safety profile and achieved responses against a variety of refractory MDM2amp, TP53-WT solid tumors, but tumor reductions were short-lived. Subsequent efforts should focus on combination strategies, further biomarker refinement, or novel MDM2 targeting approaches to achieve more durable clinical benefit.
Authors
- Christopher T. Chen (ORCID: https://orcid.org/0000-0001-8962-3527)
- Thomas E. Stinchcombe (ORCID: https://orcid.org/0000-0002-3595-8011)
- Christopher Sumey (ORCID: https://orcid.org/0000-0002-9288-2236)
- Bradley Sumrall
- Mrinal M. Gounder (ORCID: https://orcid.org/0000-0001-8468-0119)
- Robert C. Doebele (ORCID: https://orcid.org/0000-0001-6728-6857)
- Glenn J. Hanna (ORCID: https://orcid.org/0000-0002-9969-2523)
- Vijaya G. Tirunagaru (ORCID: https://orcid.org/0000-0002-6505-8858)
- Steven M. Duffy
- Kanchan Singh (ORCID: https://orcid.org/0000-0002-7140-434X)
- Trisha M. Wise‐Draper (ORCID: https://orcid.org/0000-0002-7279-4028)
- Eric E. Schadt (ORCID: https://orcid.org/0000-0002-7892-8808)
- Aviva G. Beckmann (ORCID: https://orcid.org/0000-0001-6099-6135)
- Andre Neil Forbes (ORCID: https://orcid.org/0000-0001-7201-4776)
- Xinyu Pei
- Feng Xu (ORCID: https://orcid.org/0000-0002-1172-3859)
- Gregory M. Coté (ORCID: https://orcid.org/0000-0003-0181-886X)
- Nora Ku
- Patrick Cobb (ORCID: https://orcid.org/0000-0003-0265-5425)
- Mohammed Kanaan
- Ecaterina E Ileana Dumbrava (ORCID: https://orcid.org/0000-0002-1959-0536)
Institutions
- Navicent Health (US)
- Program for Appropriate Technology in Health (US)
- Rainforest Alliance (US)
- Memorial Sloan Kettering Cancer Center (US)
- The University of Texas MD Anderson Cancer Center (US)
- Harvard University (US)
- Palo Alto University (US)
- Avera Health (US)
- University Hospital, Newark (US)
- Kettering University (US)
- Massachusetts General Hospital (US)
- Clinical Research Institute (US)
- Boundless Bio (United States) (US)
- Sanford Research (US)
- Troutlodge (United States) (US)
- Hematology Oncology Associates of Central New York (US)
- Radiation Oncology Institute (US)
- CounterPath (United States) (US)
- Dana-Farber Cancer Institute (US)
- Stanford Medicine (US)
- Cincinnati VA Medical Center (US)
- Center for Cancer Research (US)
- Northwest Medical Specialties (US)
- St. Vincent's HealthCare (US)
- Duke Cancer Institute
- University of Cincinnati (US)
- Stanford University (US)
Publication Details
- Journal
- Clinical Cancer Research
- Published
- 2025-08-11
- DOI
- https://doi.org/10.1158/1078-0432.ccr-25-0762
- Citations
- 5
- Primary Topic
- Cancer-related Molecular Pathways
- Type
- article
- Field-Weighted Citation Impact
- 5.23
Funders
- Gilead Sciences
- Chordoma Foundation
- Regeneron Pharmaceuticals
- Merck KGaA
- Jazz Pharmaceuticals
- Foghorn Therapeutics
- MacroGenics
- Coherus Biosciences
- Eisai
- Servier
- PharmaMar
- Bavarian Nordic
- National Institutes of Health
- EMD Serono
- National Cancer Institute